Taha Mohamad R, Tyring Stephen K
School of Medicine, Texas A&M University Health Science Center, Bryan, TX, USA.
Center for Clinical Studies, Webster, TX, USA.
Skin Therapy Lett. 2025 May;30(3):1-3.
Prurigo nodularis and atopic dermatitis are chronic, inflammatory skin conditions characterized by significant pruritus that disrupts daily life. They also involve dysfunction of the T-helper 2 immune response, leading to the over secretion of interleukin-31 (IL-13) in the dermis and serum. Nemolizumab is a new IL-31 receptor antagonist that has shown high efficacy in the treatment of prurigo nodularis (PN) and atopic dermatitis (AD) in multiple phase 3 trials, with a good safety profile. A brief overview of PN and AD including highlights of the findings from three trials of nemolizumab in treating these disorders will be presented herein.
结节性痒疹和特应性皮炎是慢性炎症性皮肤病，其特征为严重瘙痒，扰乱日常生活。它们还涉及辅助性T细胞2免疫反应功能障碍，导致真皮和血清中白细胞介素-31（IL-13）分泌过多。奈莫利珠单抗是一种新型IL-31受体拮抗剂，在多项3期试验中已显示出对结节性痒疹（PN）和特应性皮炎（AD）的治疗具有高效性，且安全性良好。本文将简要概述PN和AD，包括奈莫利珠单抗治疗这些疾病的三项试验结果要点。
